Agenus Inc (AGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Agenus Inc (AGEN) has a cash flow conversion efficiency ratio of 0.158x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.95 Million) by net assets ($-227.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AGEN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Agenus Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Agenus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Agenus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agenus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reef Casino Trust
AU:RCT
|
0.925x |
|
Gabelli Global Small and Mid Cap Value Closed Fund
NYSE:GGZ
|
0.000x |
|
Tainergy Tech Co Ltd
TW:4934
|
-0.035x |
|
GR Silver Mining Ltd
V:GRSL
|
-0.097x |
|
Mincon Group plc
IR:MIO
|
0.007x |
|
Reyon Pharmaceutical Co Ltd
KO:102460
|
-0.007x |
|
Rav Bariach 08 Industries Ltd
TA:BRIH
|
0.051x |
|
Pioneer Floating Rate Trust
NYSE:PHD
|
0.054x |
Annual Cash Flow Conversion Efficiency for Agenus Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Agenus Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Agenus Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-277.86 Million | $-158.31 Million | 0.570x | +10.28% |
| 2024-12-31 | $-306.42 Million | $-158.31 Million | 0.517x | -65.81% |
| 2023-12-31 | $-148.38 Million | $-224.20 Million | 1.511x | -52.70% |
| 2022-12-31 | $-54.90 Million | $-175.37 Million | 3.194x | +1408.48% |
| 2021-12-31 | $47.91 Million | $10.14 Million | 0.212x | -67.80% |
| 2020-12-31 | $-211.50 Million | $-139.10 Million | 0.658x | +714.39% |
| 2019-12-31 | $-231.34 Million | $-18.68 Million | 0.081x | -89.25% |
| 2018-12-31 | $-174.55 Million | $-131.09 Million | 0.751x | -39.57% |
| 2017-12-31 | $-75.82 Million | $-94.23 Million | 1.243x | -39.19% |
| 2016-12-31 | $-39.13 Million | $-79.96 Million | 2.044x | +406.40% |
| 2015-12-31 | $70.73 Million | $-47.18 Million | -0.667x | +59.85% |
| 2014-12-31 | $23.02 Million | $-38.23 Million | -1.661x | -138.11% |
| 2013-12-31 | $-4.48 Million | $-19.53 Million | 4.359x | +5274.33% |
| 2012-12-31 | $-12.02 Million | $1.01 Million | -0.084x | -110.80% |
| 2011-12-31 | $-20.83 Million | $-16.25 Million | 0.780x | -22.26% |
| 2010-12-31 | $-14.71 Million | $-14.76 Million | 1.003x | -29.59% |
| 2009-12-31 | $-16.98 Million | $-24.19 Million | 1.425x | +17.91% |
| 2008-12-31 | $-23.92 Million | $-28.91 Million | 1.209x | +113.12% |
| 2007-12-31 | $-47.06 Million | $-26.69 Million | 0.567x | -78.05% |
| 2006-12-31 | $-17.39 Million | $-44.94 Million | 2.584x | +224.26% |
| 2005-12-31 | $31.90 Million | $-66.33 Million | -2.079x | -267.49% |
| 2004-12-31 | $106.44 Million | $-60.22 Million | -0.566x | -16.33% |
| 2003-12-31 | $105.25 Million | $-51.19 Million | -0.486x | +25.60% |
| 2002-12-31 | $77.76 Million | $-50.83 Million | -0.654x | -34.79% |
| 2001-12-31 | $75.92 Million | $-36.83 Million | -0.485x | -274.02% |
| 2000-12-31 | $116.70 Million | $-15.13 Million | -0.130x | +50.34% |
| 1999-12-31 | $51.70 Million | $-13.50 Million | -0.261x | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more